Eisai and Nuvation Bio said on March 27 that a regulatory application for the oral ROS1 tyrosine kinase inhibitor taletrectinib is now under European review for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC). The application, submitted to…
To read the full story
Related Article
- UK Accepts Taletrectinib Filing for ROS1+ NSCLC: Eisai
June 29, 2026
- Eisai Picks Up Rights to Nuvation’s Taletrectinib in Europe, Other Regions
January 14, 2026
BUSINESS
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





